NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
18.03
+0.21 (1.18%)
Nov 4, 2024, 4:00 PM EST - Market closed
NAMS Employees
NewAmsterdam Pharma Company had 29 employees as of December 31, 2023. The number of employees increased by 12 or 70.59% compared to the previous year.
Employees
29
Change (1Y)
12
Growth (1Y)
70.59%
Revenue / Employee
$256,000
Profits / Employee
-$7,910,414
Market Cap
1.62B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 29 | 12 | 70.59% |
Dec 31, 2022 | 17 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Teladoc Health | 5,600 |
AtriCure | 1,200 |
Immunocore Holdings | 497 |
Dynavax Technologies | 408 |
Harrow | 315 |
Kiniksa Pharmaceuticals International, | 297 |
Bicycle Therapeutics | 284 |
Rocket Pharmaceuticals | 268 |
NAMS News
- 3 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - GlobeNewsWire
- 4 weeks ago - Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies - Seeking Alpha
- 2 months ago - NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
- 2 months ago - NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside - Benzinga
- 3 months ago - NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 - GlobeNewsWire
- 4 months ago - NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors - GlobeNewsWire
- 4 months ago - NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period - Seeking Alpha